1210 related articles for article (PubMed ID: 15665416)
1. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
2. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
3. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
4. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA; Gu Z; Nakamura T
Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
[TBL] [Abstract][Full Text] [Related]
6. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
7. Dementia of Alzheimer's disease and other neurodegenerative disorders--memantine, a new hope.
Sonkusare SK; Kaul CL; Ramarao P
Pharmacol Res; 2005 Jan; 51(1):1-17. PubMed ID: 15519530
[TBL] [Abstract][Full Text] [Related]
8. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
9. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease.
Rogawski MA; Wenk GL
CNS Drug Rev; 2003; 9(3):275-308. PubMed ID: 14530799
[TBL] [Abstract][Full Text] [Related]
10. N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease.
Olivares D; Deshpande VK; Shi Y; Lahiri DK; Greig NH; Rogers JT; Huang X
Curr Alzheimer Res; 2012 Jul; 9(6):746-58. PubMed ID: 21875407
[TBL] [Abstract][Full Text] [Related]
11. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
12. Pharmacotherapeutic approaches to the treatment of Alzheimer's disease.
Standridge JB
Clin Ther; 2004 May; 26(5):615-30. PubMed ID: 15220008
[TBL] [Abstract][Full Text] [Related]
13. Neuropathologic changes in Alzheimer's disease: potential targets for treatment.
Wenk GL
J Clin Psychiatry; 2006; 67 Suppl 3():3-7; quiz 23. PubMed ID: 16649845
[TBL] [Abstract][Full Text] [Related]
14. Possible role for memantine in protecting retinal ganglion cells from glaucomatous damage.
Lipton SA
Surv Ophthalmol; 2003 Apr; 48 Suppl 1():S38-46. PubMed ID: 12852433
[TBL] [Abstract][Full Text] [Related]
15. NMDA-antagonism (memantine): an alternative pharmacological therapeutic principle in Alzheimer's and vascular dementia.
Koch HJ; Szecsey A; Haen E
Curr Pharm Des; 2004; 10(3):253-9. PubMed ID: 14754385
[TBL] [Abstract][Full Text] [Related]
16. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
17. Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity.
Chen HS; Pellegrini JW; Aggarwal SK; Lei SZ; Warach S; Jensen FE; Lipton SA
J Neurosci; 1992 Nov; 12(11):4427-36. PubMed ID: 1432103
[TBL] [Abstract][Full Text] [Related]
18. Neuroprotective concentrations of the N-methyl-D-aspartate open-channel blocker memantine are effective without cytoplasmic vacuolation following post-ischemic administration and do not block maze learning or long-term potentiation.
Chen HS; Wang YF; Rayudu PV; Edgecomb P; Neill JC; Segal MM; Lipton SA; Jensen FE
Neuroscience; 1998 Oct; 86(4):1121-32. PubMed ID: 9697119
[TBL] [Abstract][Full Text] [Related]
19. Memantine: targeting glutamate excitotoxicity in Alzheimer's disease and other dementias.
Molinuevo JL; Lladó A; Rami L
Am J Alzheimers Dis Other Demen; 2005; 20(2):77-85. PubMed ID: 15844753
[TBL] [Abstract][Full Text] [Related]
20. Management of moderate to severe Alzheimer's disease: focus on memantine.
Dominguez E; Chin TY; Chen CP; Wu TY
Taiwan J Obstet Gynecol; 2011 Dec; 50(4):415-23. PubMed ID: 22212311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]